{
    "id": 16302,
    "fullName": "NTRK1 G667C",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NTRK1 G667C lies within the protein kinase domain of the Ntrk1 protein (UniProt.org). G667C has been demonstrated to confer resistance to Ntrk inhibitors as a secondary resistance mutation in the context of NTRK1 fusions (PMID: 28751539, PMID: 26546295), but has not been biochemically characterized and therefore, its effect on Ntrk1 protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 4298,
                    "pubMedId": 26546295,
                    "title": "Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26546295"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4914,
        "geneSymbol": "NTRK1",
        "terms": [
            "NTRK1",
            "MTC",
            "p140-TrkA",
            "TRK",
            "Trk-A",
            "TRK1",
            "TRKA"
        ]
    },
    "variant": "G667C",
    "createDate": "01/12/2016",
    "updateDate": "11/03/2019",
    "referenceTranscriptCoordinates": {
        "id": 112570,
        "transcript": "NM_002529",
        "gDna": "chr1:g.156879315G>T",
        "cDna": "c.1999G>T",
        "protein": "p.G667C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3927,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Rozlytrek (entrectinib) treatment resulted in partial response for 4 months in a colorectal cancer patient harboring a LMNA-NTRK1 gene fusion, followed by development of drug resistance that was attributed to acquired NTRK1 G595R and NTRK1 G667C mutations (PMID: 26546295).",
            "molecularProfile": {
                "id": 16584,
                "profileName": "LMNA - NTRK1 NTRK1 G595R NTRK1 G667C"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4298,
                    "pubMedId": 26546295,
                    "title": "Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26546295"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11260,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line oncogenic mouse model expressing an NTRK1 activating mutation and a secondary resistance mutation, NTRK1 G667C, was sensitive to treatment with LOXO-195, demonstrating inhibition of tumor growth (PMID: 28578312).",
            "molecularProfile": {
                "id": 27939,
                "profileName": "NTRK1 G667C NTRK1 act mut"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11261,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a cell line oncogenic mouse model expressing an NTRK1 activating mutation and a secondary resistance mutation, NTRK1 G667C, demonstrated a decrease response when treated with Vitrakvi (larotrectinib) (PMID: 28578312).",
            "molecularProfile": {
                "id": 27939,
                "profileName": "NTRK1 G667C NTRK1 act mut"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9187,
                    "pubMedId": 28578312,
                    "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578312"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13168,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPM3-NTRK1 and NTRK1 G667C were sensitive to Foretinib (GSK1363089) in culture, demonstrating growth inhibition (PMID: 28751539).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited phosphorylation of NTRK1 and downstream AKT and reduced viability of cells expressing TPM3-NTRK1 with NTRK1 G667C in culture (PMID: 29463555).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11364,
                    "pubMedId": 29463555,
                    "title": "Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29463555"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13170,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing TPM3-NTRK1 and NTRK1 G667C were sensitive to Ofev (nintedanib) in culture, demonstrating growth inhibition (PMID: 28751539).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13922,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ofev (nintedanib) inhibited NTRK1 phosphorylation and viability of cells expressing TPM3-NTRK1 with NTRK1 G667C in culture (PMID: 29463555).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11364,
                    "pubMedId": 29463555,
                    "title": "Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29463555"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13917,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquisition NTRK1 G667C conferred resistance to Rozlytrek (entrectinib) in a colon cancer cell line harboring TPM3-NTRK1 in xenograft models (PMID: 29463555).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11364,
                    "pubMedId": 29463555,
                    "title": "Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29463555"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13166,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing TPM3-NTRK1 and NTRK1 G667C were resistant to Vitrakvi (larotrectinib) in culture (PMID: 28751539).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20643,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing TPM3-NTRK1 and NTRK1 G667C were resistant to treatment with DS6051b in culture (PMID: 31399568).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13169,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing TPM3-NTRK1 and NTRK1 G667C were sensitive to Iclusig (ponatinib) in culture, demonstrating growth inhibition (PMID: 28751539).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14122,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse model expressing TPM3-NTRK1 and NTRK1 G667C was sensitive to treatment with Merestinib (LY2801653), demonstrating tumor regression (PMID: 29568395).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11467,
                    "pubMedId": 29568395,
                    "title": "Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29568395"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13167,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing TPM3-NTRK1 and NTRK1 G667C were sensitive to Cometriq (Cabometyx, cabozantinib) in culture, demonstrating growth inhibition (PMID: 28751539).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13920,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rozlytrek (entrectinib) did not inhibit phosphorylation of NTRK1 or viability of cells expressing TPM3-NTRK1 with NTRK G667C in culture (PMID: 29463555).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11364,
                    "pubMedId": 29463555,
                    "title": "Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29463555"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13165,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPM3-NTRK1 and NTRK1 G667C were resistant to Rozlytrek (entrectinib) in culture (PMID: 28751539).",
            "molecularProfile": {
                "id": 29018,
                "profileName": "TPM3 - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16267,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH7057288 inhibited growth of cells expressing MPRIP-NTRK1 harboring NTRK1 G667C in culture, and induced tumor regression in xenograft models (PMID: 30242093).",
            "molecularProfile": {
                "id": 31577,
                "profileName": "MPRIP - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 7977,
                "therapyName": "CH7057288",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14399,
                    "pubMedId": 30242093,
                    "title": "Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30242093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16583,
            "profileName": "NTRK1 G667C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16584,
            "profileName": "LMNA - NTRK1 NTRK1 G595R NTRK1 G667C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27939,
            "profileName": "NTRK1 G667C NTRK1 act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29018,
            "profileName": "TPM3 - NTRK1 NTRK1 G667C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31577,
            "profileName": "MPRIP - NTRK1 NTRK1 G667C",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 112570,
            "transcript": "NM_002529",
            "gDna": "chr1:g.156879315G>T",
            "cDna": "c.1999G>T",
            "protein": "p.G667C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}